ReviewPhysiological reviews2013
Nuclear receptors in bone physiology and diseases.
Review in Physiological reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Osteoglycin and Bone-a Systematic Review.Current osteoporosis reports · 2019Pooled it
- Estrogen signaling in PDGFRα+ cells positively regulates cortical bone metabolism via IGFBP5 in female mice.JBMR plus · 2026Article
- Sulforaphene Mitigates Periodontitis by NRF2-Dependent Regulation ofFood science & nutrition · 2025Article
- Nuclear farnesoid X receptor protects against bone loss by driving osteoblast differentiation through stabilizing RUNX2.Bone research · 2025Article
- FXR Activation Accelerates Early Phase of Osteoblast Differentiation Through COX-2-PGEMolecules (Basel, Switzerland) · 2024Article
- Sex steroid hormones: an overlooked yet fundamental factor in oral homeostasis in humans.Frontiers in endocrinology · 2024Review
- Role and Regulation of Transcription Factors in Osteoclastogenesis.International journal of molecular sciences · 2023Review
- Skeletal effects following developmental flame-retardant exposure are specific to sex and chemical class in the adult Wistar rat.Frontiers in toxicology · 2023Article
- The Highly Potent AhR Agonist Picoberin Modulates Hh-Dependent Osteoblast Differentiation.Journal of medicinal chemistry · 2022Article
- Sex Steroid Regulation of Oxidative Stress in Bone Cells: An In Vitro Study.International journal of environmental research and public health · 2021Article
- Biological basis of bone strength: anatomy, physiology and measurement.Journal of musculoskeletal & neuronal interactions · 2020Review
- Nuclear receptors in osteoclasts.Current opinion in pharmacology · 2020Review
- Effects of bazedoxifene and low-intensity aerobic exercise on bone and fat parameters in ovariectomized rats.Journal of bone and mineral metabolism · 2020Article
- Synthesis of Novel Farnesoid X Receptor Agonists and Validation of Their Efficacy in Activating Differentiation of Mouse Bone Marrow-Derived Mesenchymal Stem Cells into Osteoblasts.Molecules (Basel, Switzerland) · 2019Article
- Hepatitis B Virus X Protein-Induced RORBioMed research international · 2019Article
- Pyk2 deficiency potentiates osteoblast differentiation and mineralizing activity in response to estrogen or raloxifene.Molecular and cellular endocrinology · 2018Article
- Mathematical Models in the Description of Pregnane X Receptor (PXR)-Regulated Cytochrome P450 Enzyme Induction.International journal of molecular sciences · 2018Review
- GPER modulators: Opportunity Nox on the heels of a class Akt.The Journal of steroid biochemistry and molecular biology · 2018Review
- The Human Carbonic Anhydrase II in Platelets: An Underestimated Field of Its Activity.BioMed research international · 2018Review
- Nuclear receptor and VEGF pathways for gene-blood lead interactions, on bone mineral density, in Korean smokers.PloS one · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the last decade, our view on the skeleton as a mere solid physical support structure has been transformed, as bone emerged as a dynamic, constantly remodeling tissue with systemic regulatory functions including those of an endocrine organ. Reflecting this remarkable functional complexity, distinct classes of humoral and intracellular regulatory factors have been shown to control vital processes in the bone. Among these regulators, nuclear receptors (NRs) play fundamental roles in bone development, growth, and maintenance. NRs are DNA-binding transcription factors that act as intracellular transducers of the respective ligand signaling pathways through modulation of expression of specific sets of cognate target genes. Aberrant NR signaling caused by receptor or ligand deficiency may profoundly affect bone health and compromise skeletal functions. Ligand dependency of NR action underlies a major strategy of therapeutic intervention to correct aberrant NR signaling, and significant efforts have been made to design novel synthetic NR ligands with enhanced beneficial properties and reduced potential negative side effects. As an example, estrogen deficiency causes bone loss and leads to development of osteoporosis, the most prevalent skeletal disorder in postmenopausal women. Since administration of natural estrogens for the treatment of osteoporosis often associates with undesirable side effects, several synthetic estrogen receptor ligands have been developed with higher therapeutic efficacy and specificity. This review presents current progress in our understanding of the roles of various nuclear receptor-mediated signaling pathways in bone physiology and disease, and in development of advanced NR ligands for treatment of common skeletal disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.